Merck completes acquisition of EyeBio
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Subscribe To Our Newsletter & Stay Updated